Pharmaceutical giant Pfizer announced a significant acquisition on Monday, agreeing to purchase Metsera, a leading developer of weight-loss medications, for up to $7.3 billion. This strategic move underscores Pfizer's ambition to capitalize on the rapidly expanding obesity drug market, projected to reach a value of approximately $100 billion by the 2030s. The deal involves an initial cash payment of $47.50 per share, representing a substantial 43% premium over Metsera's closing price on Friday. Further contingent payments, totaling up to $22.50 per share, are tied to the clinical and regulatory success of Metsera's drug pipeline. The acquisition is expected to finalize by the end of the year.
This strategic move follows a series of setbacks for Pfizer in its own obesity drug development efforts. Earlier this year, the company discontinued two promising candidates due to safety concerns, highlighting the inherent risks and complexities of this therapeutic area. The acquisition of Metsera offers Pfizer immediate access to a diverse pipeline of both oral and injectable treatments, potentially accelerating its entry into this lucrative market.
Metsera, established in 2022, has quickly assembled an impressive portfolio through strategic licensing and acquisition deals. Its most advanced candidate, MET-233i, a GLP-1 drug, demonstrated significant weight loss in early-stage trials, with participants losing up to 8.4% of their body weight within 36 days. The company is developing MET-233i as a once-monthly injectable, offering a potential advantage over existing weekly injections. Additionally, Metsera's pipeline includes a monthly drug targeting the amylin hormone and two oral GLP-1 candidates poised to enter clinical trials shortly.
Analysts are largely optimistic about the acquisition's potential. Leerink Partners projects Metsera's obesity drug candidates to generate over $5 billion in peak annual sales. JPMorgan analysts concur, stating that Metsera's experimental drugs should significantly accelerate Pfizer's market entry. The acquisition positions Pfizer to compete directly with established players like Eli Lilly and Novo Nordisk, who have already achieved significant success with their weight-loss injections. Pfizer CEO Albert Bourla emphasized the strategic alignment of this acquisition with the company's investment priorities, highlighting the opportunity to leverage Pfizer's extensive experience and infrastructure to rapidly advance Metsera's pipeline and establish a leading position in the burgeoning obesity treatment market. Metsera's successful IPO earlier this year solidified its position as a key player in this rapidly developing sector.
---
Originally published at: https://www.cnbc.com/2025/09/22/pfizer-to-buy-weight-loss-drug-developer-metsera.html
